摘要
目的通过检测血清胃蛋白酶原Ⅰ(pepsinogen I,PGI)、Ⅱ(PGII)的含量,探讨胃溃疡及胃癌患者治疗前后血清PGI、PGII及PGI/PGII的变化规律。方法收集2005年5月至2007年5月在我院消化内镜中心行胃镜检查确诊为消化性溃疡患者48例,胃癌33例(其中复发病例13例),并设正常对照组,采用免疫比浊法(immunoturbidimetric assay)测定治疗前后患者血清PGI及PGII含量,并计算PGI/PGII即PGR。结果消化性溃疡患者血清PGI及PGII分别为(180.15±41.12)mg/L及(23.76±7.57)mg/L,较对照组明显升高(P﹤0.05),而在治愈后与正常组比较无显著性差异。胃癌患者血清PGI及PGR分别为(94.05±40.74)mg/L、5.97±3.33,较对照组明显降低(P﹤0.05),术后较术前降低更为明显。复发者PGI及PGII分别为(97.65±37.44)mg/L和(16.10±5.72)mg/L,较术后明显升高(P﹤0.05)。结论测定血清PGI、PGII及PGR值对胃溃疡及胃癌患者疗效的判定及复发诊断具有重要的参考意义。
Objective To study serum pepsinogen I （PGI）, serum pepsinogen II （PGII） level and the PGI/PGII ratio （PGR） in patients with gastric ulcer and gastric cancer before and after treatment. Methods Serum PGI and PGII levels were measured by immunoturbidimetric assay in healthy controls, 48 patients with gastric peptic ulcer and 33 patients with gastric cancer （13 patients with recurrence of gastric cancer）. Results Before treatment, the serum levels of PGI and PGII in peptic ulcer patients were （180.15±41.12）mg/L and （23.76±7.57）mg/L respectively which were significantly higher than that of healthy controls （P﹤0.05）, but there was no difference in that between patients in the healing stage of peptic ulcer after treatment and healthy controls. The serum level of PGI and PGR in gastric cancer patients was （94.05±40.74）mg/L and 5.97±3.33 respectively, which were significantly lower than that of healthy controls （P﹤0.05）. Compared with pre-operation group, serum levels of PGI and PGR [（97.65±37.44）mg/L and （16.10±5.72）mg/L] in patients with recurrence of gastric cancer after operation were significantly higher than that of those without recurrence （P﹤0.05）. Conclusions The determination of serum PGI and PGII was not only helpful for evaluating therapeutic effect in gastric ulcer and gastric cancer, but also can provide important clues in detecting recurrence of gastric cancer.
出处
《北京医学》
CAS
2008年第4期224-226,共3页
Beijing Medical Journal
